pharmaphorum2d
Novartis takes $485m hit after axing eczema drug from pipeline
Spain’s Almirall is another company hoping to take on Sanofi – it has licensed in lebrikizumab from Dermira ... which has a different mechanism of action focused on IL-4.
FDA approves Ebglyss for moderate-to-severe atopic dermatitis
The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 ...
Medscape6d
FDA Approves Lebrikizumab for Atopic Dermatitis
The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for the treatment of adults and children age 12 years and older who have ...
The American Journal of Managed Care4d
FDA Approves Lebrikizumab For Patients Aged 12 and Older With Moderate to Severe Atopic Dermatitis
The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older with moderate to severe atopic dermatitis (AD). The FDA approved ...
Medscape6d
Topical and Systemic Therapies for Nickel Allergy
The low-nickel diet and hyposensitization therapy with oral nickel is at present the only therapy that acts on the pathogenetic mechanisms of this condition, so it could be considered the only ...
Monthly Prescribing Reference4d
Ebglyss Approved for Moderate to Severe Atopic Dermatitis
Credit: Lilly The approval of Ebglyss, an interleukin-13 antagonist, was supported by data from 3 clinical trials. Ebglyss can be used with or without topical corticosteroids. The Food and Drug ...
Yahoo Finance6d
FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis
13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor ...
FiercePharma4d
Lilly's immunology unit scores another FDA nod with eczema treatment Ebglyss
The company said it plans to launch Ebglyss, also known as lebrikizumab, in the coming weeks but is not yet divulging its price in the U.S. The nod comes on top of Lilly expanding its label for ...
pharmaphorum4d
Look out Dupixent, Lilly's lebrikizumab is on the march
Eli Lilly had a lot riding on its two phase 3 trials of IL-13 inhibitor lebrikizumab in atopic dermatitis (AD) – and it now looks like it has backed a winner. The company has claimed across-the ...
Stockhouse6d
FDA Approves Lilly's EBGLYSS(TM) (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis
INDIANAPOLIS, Sept. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 ...
MedCity News4d
New Eli Lilly Eczema Drug Brings Competition and Dosing Edge Versus Sanofi, LEO Pharma Meds
The Lilly drug, lebrikizumab, will be marketed as Ebglyss, which is the same brand name for the product in Europe and Japan where it has already been approved. The excessive immune response in ...